DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.
| Image |  |
|---|---|
| Description | scientific article published on 21 May 2014 |
| Author/s |
author: Francesco Grossi Dariusz M Kowalski |
| Publication date | May 21, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |